Literature DB >> 29321166

Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study.

Anne K Örtqvist1, Cecilia Lundholm1, Jonas Halfvarson2, Jonas F Ludvigsson1,3, Catarina Almqvist1,4.   

Abstract

OBJECTIVE: Earlier studies on antibiotics exposure and development of IBD (Crohn's disease (CD) and ulcerative colitis (UC)) may have been biased by familial factors and gastroenteritis. We aimed to estimate the association between antibiotics during pregnancy or infantile age and very early onset (VEO) IBD.
DESIGN: In this cohort study of 827 239 children born in Sweden between 2006 and 2013, we examined the link between exposure to systemic antibiotics and VEO-IBD (diagnosis <6 years of age), using Cox proportional hazard regression models. Information on antibiotics and IBD was retrieved from the nationwide population-based Swedish Prescribed Drug Register and the National Patient Register. We specifically examined potential confounding from parental IBD and gastroenteritis.
RESULTS: Children exposed to antibiotics during pregnancy were at increased risk of IBD compared with general population controls (adjusted HR (aHR) 1.93; 95% CI 1.06 to 3.50). Corresponding aHRs were 2.48 (95% CI 1.01 to 6.08) for CD and 1.25 (95% CI 0.47 to 3.26) for UC, respectively. For antibiotics in infantile age, the aHR for IBD was 1.11 (95% CI 0.57 to 2.15); for CD 0.72 (95% CI 0.27 to 1.92) and 1.23 (95% CI 0.45 to 3.39) for UC. Excluding children with gastroenteritis 12 months prior to the first IBD diagnosis retained similar aHR for antibiotics during pregnancy and CD, while the association no longer remained significant for IBD.
CONCLUSION: We found that exposure to antibiotics during pregnancy, but not in infantile age, is associated with an increased risk of VEO-IBD regardless of gastroenteritis. The risk increase for exposure in pregnancy may be due to changes in the microbiota. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  antibiotics; crohn’s colitis; epidemiology; inflammatory bowel disease; ulcerative colitis

Mesh:

Substances:

Year:  2018        PMID: 29321166     DOI: 10.1136/gutjnl-2017-314352

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  36 in total

Review 1.  Influence of maternal microbiota during pregnancy on infant immunity.

Authors:  D D Nyangahu; H B Jaspan
Journal:  Clin Exp Immunol       Date:  2019-06-21       Impact factor: 4.330

Review 2.  Imprinting of the immune system by the microbiota early in life.

Authors:  Ziad Al Nabhani; Gérard Eberl
Journal:  Mucosal Immunol       Date:  2020-01-27       Impact factor: 7.313

Review 3.  Challenges in IBD Research: Environmental Triggers.

Authors:  Shuk-Mei Ho; James D Lewis; Emeran A Mayer; Scott E Plevy; Emil Chuang; Stephen M Rappaport; Kenneth Croitoru; Joshua R Korzenik; Jeffrey Krischer; Jeffrey S Hyams; Richard Judson; Manolis Kellis; Michael Jerrett; Gary W Miller; Melanie L Grant; Nataly Shtraizent; Gerard Honig; Andrés Hurtado-Lorenzo; Gary D Wu
Journal:  Inflamm Bowel Dis       Date:  2019-05-16       Impact factor: 5.325

Review 4.  Ambient Air Pollution and Pediatric Inflammatory Bowel Diseases: An Updated Scoping Review.

Authors:  Ricardo G Suarez; Alvaro R Osornio-Vargas; Eytan Wine
Journal:  Dig Dis Sci       Date:  2022-06-25       Impact factor: 3.487

Review 5.  Microbiota succession throughout life from the cradle to the grave.

Authors:  Cameron Martino; Amanda Hazel Dilmore; Zachary M Burcham; Jessica L Metcalf; Dilip Jeste; Rob Knight
Journal:  Nat Rev Microbiol       Date:  2022-07-29       Impact factor: 78.297

6.  Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution.

Authors:  J Garrido-Mesa; A Rodríguez-Nogales; F Algieri; T Vezza; L Hidalgo-Garcia; M Garrido-Barros; M P Utrilla; F Garcia; N Chueca; M E Rodriguez-Cabezas; N Garrido-Mesa; J Gálvez
Journal:  Br J Pharmacol       Date:  2018-10-15       Impact factor: 8.739

7.  Early-Life Exposure to Antibiotics and Risk for Crohn's Disease: A Nationwide Danish Birth Cohort Study.

Authors:  Anders Mark-Christensen; Aksel Lange; Rune Erichsen; Trine Frøslev; Buket Öztürk Esen; Henrik Toft Sørensen; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 5.325

8.  Early life exposures and the risk of inflammatory bowel disease: Systematic review and meta-analyses.

Authors:  Manasi Agrawal; João Sabino; Catarina Frias-Gomes; Christen M Hillenbrand; Celine Soudant; Jordan E Axelrad; Shailja C Shah; Francisco Ribeiro-Mourão; Thomas Lambin; Inga Peter; Jean-Frederic Colombel; Neeraj Narula; Joana Torres
Journal:  EClinicalMedicine       Date:  2021-05-15

9.  Early-Life Microbial Restitution Reduces Colitis Risk Promoted by Antibiotic-Induced Gut Dysbiosis in Interleukin 10-/- Mice.

Authors:  Jun Miyoshi; Sawako Miyoshi; Tom O Delmont; Candace Cham; Sonny T M Lee; Aki Sakatani; Karen Yang; Yue Shan; Megan Kennedy; Evan Kiefl; Mahmoud Yousef; Sean Crosson; Mitchell Sogin; Dionysios A Antonopoulos; A Murat Eren; Vanessa Leone; Eugene B Chang
Journal:  Gastroenterology       Date:  2021-06-07       Impact factor: 33.883

10.  Maternal cecal microbiota transfer rescues early-life antibiotic-induced enhancement of type 1 diabetes in mice.

Authors:  Xue-Song Zhang; Yue Sandra Yin; Jincheng Wang; Thomas Battaglia; Kimberly Krautkramer; Wei Vivian Li; Jackie Li; Mark Brown; Meifan Zhang; Michelle H Badri; Abigail J S Armstrong; Christopher M Strauch; Zeneng Wang; Ina Nemet; Nicole Altomare; Joseph C Devlin; Linchen He; Jamie T Morton; John Alex Chalk; Kelly Needles; Viviane Liao; Julia Mount; Huilin Li; Kelly V Ruggles; Richard A Bonneau; Maria Gloria Dominguez-Bello; Fredrik Bäckhed; Stanley L Hazen; Martin J Blaser
Journal:  Cell Host Microbe       Date:  2021-07-21       Impact factor: 31.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.